TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00695552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low impact exercise
Description: Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
Study: NCT03113695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDMP
Description: methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
Study: NCT00606983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: oral administration of Tamsulosin
Study: NCT01920737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT04464070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PGD2
Description: labeled precursor
Study: NCT03669224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nano Care Gold
Description: Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
Study: NCT03944889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position
Study: NCT00869609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GLB Traditional Maintenance (TM)
Description: After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GLB-Carb-focused Maintenance (CF)
Description: After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
Study: NCT01920737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-MP (6-Mercaptopurine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT/PET scans
Description: PET or CT scan every 6 months for 3 years
Study: NCT01424566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (GA-0034)
Study: NCT02759536

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boronophenylalanine and IHNI-based BNCT
Description: Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
Study: NCT03029507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Enhanced ShipShape
Description: The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ShipShape (SS)
Description: The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
Study: NCT01295424

Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no interventions
Study: NCT02340390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G7
Description: The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exceed ABT
Description: The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
Study: NCT01981681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study: NCT00689793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
Study: NCT03102567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 50mg q.d.
Description: oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: oral gelatin capsule containing placebo to match study arm 1 - q.d. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 250 loading dose and 50mg q.d. maintenance dose
Description: Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
Study: NCT03522727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single self-incentivising implementation intention
Description: Participants are asked to form a single self-incentivising implementation intention (if-then plans)
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
Study: NCT03522727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple self-incentivising implementation intentions
Description: Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
Study: NCT03522727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-generated self-incentivising implementation intentions
Description: Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
Study: NCT02189707

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium 1x1010 cfu
Description: Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium 1x109 cfu
Description: Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder in capsules
Description: Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
Study: NCT02591459

Intervention type: OTHER
Group type: OTHER
Intervention: Using the app to assist routine anticipation
Description: Using the app to assist routine anticipation for autistic children in Android mobile devices
Study: NCT03917550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery (Transdiagnostic & self)
Description: This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic
Description: This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
Study: NCT02179541

Intervention type: OTHER
Intervention: RGB
Description: When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.

Intervention type: OTHER
Intervention: RGB
Description: When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.

Intervention type: OTHER
Intervention: RGB
Description: When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.

Intervention type: OTHER
Intervention: RGB
Description: When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
Study: NCT03598751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085
Description: 120 mg / 2 mL subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL
Study: NCT00888641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Surround kidney in ice slush for 10 minutes after arterial clamping
Study: NCT03028987

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
Study: NCT00940784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Description: Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, aspirin (81-100 mg qd) plus hydroxyurea
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
Study: NCT03024307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacists involved OPCSP
Description: This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
Study: NCT04466540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydroxychloroquine placebo
Study: NCT02165436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing gum
Description: Subjective assessment - subjective assessment of abdominal pain and nausea.
Study: NCT00940784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81-100 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 81-100 mg qd
Study: NCT02165436

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No intervention will be assessed for this group.
Study: NCT02574247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computerized auditory training
Description: 10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
Study: NCT03169647

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Listening-based intervention
Description: Participants will listen to pre-specified material on a CD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening-based intervention
Description: Participants will listen to pre-specified material on a CD